Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
Currently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Journal of Biomedicine and Biotechnology |
Online Access: | http://dx.doi.org/10.1155/2010/952047 |
id |
doaj-62ffcb8c750742c6a05e80a9bdbf9efa |
---|---|
record_format |
Article |
spelling |
doaj-62ffcb8c750742c6a05e80a9bdbf9efa2020-11-25T02:03:38ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512010-01-01201010.1155/2010/952047952047Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)Varaprasad Kolla0Paul Jenö1Suzette Moes2Sevgi Tercanli3Olav Lapaire4Mahesh Choolani5Sinuhe Hahn6Department of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandMass Spectrometry, Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, SwitzerlandMass Spectrometry, Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, SwitzerlandDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandBiomarker Discovery Laboratory, Department of Obstetrics and Gynecology, National University of Singapore, 19077, SingaporeDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandCurrently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age, as these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ labelling in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in βHCG, a known screening marker for DS, indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers.http://dx.doi.org/10.1155/2010/952047 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Varaprasad Kolla Paul Jenö Suzette Moes Sevgi Tercanli Olav Lapaire Mahesh Choolani Sinuhe Hahn |
spellingShingle |
Varaprasad Kolla Paul Jenö Suzette Moes Sevgi Tercanli Olav Lapaire Mahesh Choolani Sinuhe Hahn Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) Journal of Biomedicine and Biotechnology |
author_facet |
Varaprasad Kolla Paul Jenö Suzette Moes Sevgi Tercanli Olav Lapaire Mahesh Choolani Sinuhe Hahn |
author_sort |
Varaprasad Kolla |
title |
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) |
title_short |
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) |
title_full |
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) |
title_fullStr |
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) |
title_full_unstemmed |
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ) |
title_sort |
quantitative proteomics analysis of maternal plasma in down syndrome pregnancies using isobaric tagging reagent (itraq) |
publisher |
Hindawi Limited |
series |
Journal of Biomedicine and Biotechnology |
issn |
1110-7243 1110-7251 |
publishDate |
2010-01-01 |
description |
Currently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age, as
these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ
labelling in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in βHCG, a known screening marker for DS, indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers. |
url |
http://dx.doi.org/10.1155/2010/952047 |
work_keys_str_mv |
AT varaprasadkolla quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT pauljeno quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT suzettemoes quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT sevgitercanli quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT olavlapaire quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT maheshchoolani quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq AT sinuhehahn quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq |
_version_ |
1724946836081344512 |